Dysthymia

Lyra Health Study Finds COVID-19 Delayed Trauma Response Taking a Growing Toll on Workers’ Mental Health Worldwide

Retrieved on: 
Tuesday, March 12, 2024

Lyra Health , the leading provider of innovative Workforce Mental Health solutions for employers, today announced the findings of its 2024 State of Workforce Mental Health report .

Key Points: 
  • Lyra Health , the leading provider of innovative Workforce Mental Health solutions for employers, today announced the findings of its 2024 State of Workforce Mental Health report .
  • While organizations have made progress in promoting and supporting mental health care for mild and moderate issues such as stress and anxiety, the study also points to a rise in complex mental health conditions since 2021.
  • One of the drivers of these increases is the delayed trauma response to the COVID-19 pandemic.
  • Lyra's 2024 State of Workforce Mental Health report also revealed the second most significant factor negatively impacting U.S. workers' mental health is work-related stress and burnout.

Brain-altering fungi could lead the next frontier in mental health care

Retrieved on: 
Thursday, May 11, 2023

The series is set in a post-apocalyptic world where parasitic fungi take control of the human brain, turning people into killer zombies.

Key Points: 
  • The series is set in a post-apocalyptic world where parasitic fungi take control of the human brain, turning people into killer zombies.
  • Parasitic or “zombie” fungi that alter the mind and behaviour of their hosts do exist.
  • When spores are ingested by insects, they germinate and grow, secreting molecules that travel to the host’s brain and interfere with its function.

Fungi that alter our minds

    • In the case of humans, some fungi which produce small molecules, or metabolites, that alter our minds – and recent research shows these have therapeutic potential.
    • Humans have known about the hallucinogenic properties of fungi for centuries.
    • The Aztecs even gave magic mushrooms to people who were dying to promote a peaceful transition to the afterlife.
    • But recently, there’s been an explosion of interest in fungal metabolites, specifically because of their neurological benefits and potential in treating mental health conditions.
    • Additional studies demonstrate the positive effect of fungal metabolites in treating a range of conditions – including anxiety, depression and alcohol addiction.

No miracle cure

    • That said, psychedelics should not be considered a miracle cure as there is still a lot we don’t know.
    • Furthermore, most studies on psychedelics are still preliminary as they use a limited number of participants.
    • Furthermore, psychedelics are powerful and unpredictable – and the safety and long-term effects of such treatment is unknown.

Brain-altering fungi could lead the next frontier in mental health care – here's how

Retrieved on: 
Thursday, May 11, 2023

The series is set in a post-apocalyptic world where parasitic fungi take control of the human brain, turning people into killer zombies.

Key Points: 
  • The series is set in a post-apocalyptic world where parasitic fungi take control of the human brain, turning people into killer zombies.
  • Parasitic or “zombie” fungi that alter the mind and behaviour of their hosts do exist.
  • When spores are ingested by insects, they germinate and grow, secreting molecules that travel to the host’s brain and interfere with its function.

Fungi that alter our minds

    • In the case of humans, some fungi which produce small molecules, or metabolites, that alter our minds – and recent research shows these have therapeutic potential.
    • Humans have known about the hallucinogenic properties of fungi for centuries.
    • The Aztecs even gave magic mushrooms to people who were dying to promote a peaceful transition to the afterlife.
    • But recently, there’s been an explosion of interest in fungal metabolites, specifically because of their neurological benefits and potential in treating mental health conditions.
    • Additional studies demonstrate the positive effect of fungal metabolites in treating a range of conditions – including anxiety, depression and alcohol addiction.

No miracle cure

    • That said, psychedelics should not be considered a miracle cure as there is still a lot we don’t know.
    • Furthermore, most studies on psychedelics are still preliminary as they use a limited number of participants.
    • Furthermore, psychedelics are powerful and unpredictable – and the safety and long-term effects of such treatment is unknown.

Salman Aslam: How a Disability Diagnosis Catalyzed the Transformation of Omnicore into a Leading Healthcare Marketing Agency

Retrieved on: 
Friday, March 3, 2023

This has paved the way for digital marketing agencies such as Omnicore to offer their expertise.

Key Points: 
  • This has paved the way for digital marketing agencies such as Omnicore to offer their expertise.
  • Salman Aslam, Managing Director of Omnicore , a leading healthcare digital marketing agency, discusses the challenges his company faced and how his medical diagnosis was the catalyst for transformation and the company’s new direction into healthcare marketing.
  • The company's mission is to help medical and healthcare practices grow their businesses through digital marketing and reach their ideal patients.
  • They have managed to grow Omnicore from a small SEO consulting company to a successful agency that helps medical and healthcare practices grow their businesses through digital marketing.

Commercial Dishwashers Destroy Protective Layer in Gut

Retrieved on: 
Thursday, December 1, 2022

ZURICH, Dec. 1, 2022 /PRNewswire/ -- Whether it's at a restaurant, at school or in the barracks, commercial dishwashers help plates, glasses and cutlery become squeaky clean and dry in a matter of minutes. These practical appliances come with risks, however, as was recently discovered in a new study by researchers at the Swiss Institute of Allergy and Asthma Research (SIAF), an associated institute of the University of Zurich (UZH). One ingredient in particular found in commercial rinse agents has a toxic effect on the gastrointestinal tract.

Key Points: 
  • This damages the natural protective layer in the gut and can contribute to the onset of chronic diseases, as demonstrated by researchers working with organoids at the Swiss Institute of Allergy and Asthma Research, an associated UZH institute.
  • One ingredient in particular found in commercial rinse agents has a toxic effect on the gastrointestinal tract.
  • A typical cycle in a commercial dishwasher involves circulating hot water and detergent for around 60 seconds at high pressure.
  • Akdis calls for an immediate response: "It is important to inform the public about this risk, since alcohol ethoxylates seem to be commonly used in commercial dishwashers."

Commercial Dishwashers Destroy Protective Layer in Gut

Retrieved on: 
Thursday, December 1, 2022

ZURICH, Dec. 1, 2022 /PRNewswire/ -- Whether it's at a restaurant, at school or in the barracks, commercial dishwashers help plates, glasses and cutlery become squeaky clean and dry in a matter of minutes. These practical appliances come with risks, however, as was recently discovered in a new study by researchers at the Swiss Institute of Allergy and Asthma Research (SIAF), an associated institute of the University of Zurich (UZH). One ingredient in particular found in commercial rinse agents has a toxic effect on the gastrointestinal tract.

Key Points: 
  • This damages the natural protective layer in the gut and can contribute to the onset of chronic diseases, as demonstrated by researchers working with organoids at the Swiss Institute of Allergy and Asthma Research, an associated UZH institute.
  • One ingredient in particular found in commercial rinse agents has a toxic effect on the gastrointestinal tract.
  • A typical cycle in a commercial dishwasher involves circulating hot water and detergent for around 60 seconds at high pressure.
  • Akdis calls for an immediate response: "It is important to inform the public about this risk, since alcohol ethoxylates seem to be commonly used in commercial dishwashers."

Telehealth Startup Options MD Raised $3.8M in Pre-Seed Funding to Expand Mental Health Platform

Retrieved on: 
Tuesday, November 1, 2022

LOS ANGELES, Nov. 1, 2022 /PRNewswire/ -- Options MD, a telehealth startup providing high-quality care for treatment-resistant depression (TRD), today announced $2.35M in funding, bringing their total pre-seed funding to nearly $4M. The round was led by Bread & Butter Ventures, alongside participation from M13, Bright Ventures and Collab Capital. MedMountain Ventures and Techstars also reinvested in the company. In addition, Options MD received $100K from the Google for Startups Latino Founders Fund. The funding will enable Options MD to increase patient access to critical care and treatments that address severe and treatment-resistant mental illnesses.

Key Points: 
  • The funding will enable Options MD to increase patient access to critical care and treatments that address severe and treatment-resistant mental illnesses.
  • [1] Having watched firsthand as their family and friends struggled with mental health, Options MD was launched as a resource to deliver personalized care to mental health patients deemed "treatment resistant" by physicians.
  • Kyle Pierce, Co-Founder Options MD, said: "Options MD is addressing the white space that exists for the estimated thirty-two million patients who are most challenging to the mental health system those struggling with severe and treatment-resistant mental illnesses.
  • Options MD is a telehealth company enabling patients to access mental health care and treatment options that address severe and treatment-resistant mental illnesses.

Avadel Presents New Real-World Data Describing Demographic Characteristics and Comorbidities of Patients with Narcolepsy at ANA 2022

Retrieved on: 
Monday, October 24, 2022

DUBLIN, Ireland, Oct. 24, 2022 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, today announced new real-world data identifying demographic characteristics and comorbidities of patients with narcolepsy. These results, along with three encore presentations, were presented at the American Neurological Association (ANA) annual meeting, taking place October 22-25, 2022.

Key Points: 
  • These results, along with three encore presentations, were presented at the American Neurological Association (ANA) annual meeting, taking place October 22-25, 2022.
  • These data mark the first time we are analyzing aggregate information about patients with narcolepsy receiving treatment within the Mayo Clinic system over the last 20 years.
  • The retrospective analysis was conducted in partnership with Mayo Clinic and real-world evidence vendor nFerence using electronic health records to identify people living with narcolepsy between 2000 and 2020 and describe their demographic characteristics and comorbidities.
  • A matched control cohort was used to account for differences in demographics, care utilization and severity of illness.

Depression Drugs Global Market Report 2022: Increasing Prevalence of Mental Disorders, Such as Social Anxiety and Depression Driving Growth - ResearchAndMarkets.com

Retrieved on: 
Wednesday, October 19, 2022

The "Depression Drugs Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2022-2027" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Depression Drugs Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2022-2027" report has been added to ResearchAndMarkets.com's offering.
  • The global depression drugs market size reached US$ 17.2 Billion in 2021.
  • The increasing prevalence of mental disorders, such as social anxiety and depression, represents one of the key factors propelling the depression drugs market growth.
  • The publisher's latest report provides a deep insight into the global depression drugs market covering all its essential aspects.

Hudson Mind Introduces TMS Treatments

Retrieved on: 
Tuesday, September 13, 2022

NEW YORK, Sept. 13, 2022 /PRNewswire/ --Hudson Mind today announced its Transcranial Magnetic Stimulation (TMS) offering.

Key Points: 
  • NEW YORK, Sept. 13, 2022 /PRNewswire/ --Hudson Mind today announced its Transcranial Magnetic Stimulation (TMS) offering.
  • Launched in 2022 as the mental health division of Hudson Health (formerly Hudson Medical Group) Hudson Mind has pioneered a groundbreaking approach to treating symptoms of depression, anxiety, and PTSD.
  • Hudson Mind uses NeuroStar's TMS technology, as well as BrainsWay's Deep TMS technology.
  • Hudson Mind's treatments include Dual Sympathetic Blocks for anxiety and PTSD, ketamine infusions for anxiety and depression, and advanced Transcranial Magnetic Stimulation (TMS) for depression and OCD.